Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call
August 08 2022 - 9:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage
biopharmaceutical company dedicated to the research, development
and commercialization of innovative therapies for rare diseases of
the eye, today announced that it will report second quarter 2022
financial results on Thursday, August 11, 2022. Management will
host a conference call and live audio webcast to discuss these
results and provide a business update at 8:00 a.m. ET.
The dial-in number to access the conference call is 800-715-9871
using the conference ID 9372651. To access a live webcast and
subsequent archived recording of the call, please visit the
“Presentations” section of the Kala website at
http://kalarx.com.
About Kala Pharmaceuticals,
Inc.
Kala is a clinical-stage biopharmaceutical company dedicated to
the research, development and commercialization of innovative
therapies for rare diseases of the eye. Kala’s biologics-based
investigational therapies utilize Kala’s proprietary Mesenchymal
Stem Cell Secretome (MSC-S) platform. Kala’s lead product
candidate, KPI-012, is in clinical development for the treatment of
persistent corneal epithelial defect (PCED), a rare disease of
impaired corneal healing, which has received orphan drug
designation from the U.S. Food and Drug Administration. Kala is
also targeting KPI-012 for the treatment of Partial Limbal Stem
Cell Deficiency and ocular manifestations of moderate-to-severe
Sjögren's and plans to initiate preclinical studies to evaluate the
utility of its MSC-S platform for retinal degenerative diseases,
such as Retinitis Pigmentosa and Stargardt Disease. For more
information on Kala, please visit www.kalarx.com.
Investor Contact:
Hannah
Deresiewiczhannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024